Cellectis (CLLS) Other Non-Current Assets (2014 - 2026)
Cellectis (CLLS) posted quarterly Other Non-Current Assets of $21.3 million for Q1 2026, up 58.34% year-over-year from $13.4 million in Q1 2025, and up 6.3% quarter-over-quarter from $20.0 million in Q4 2025.
Cellectis (CLLS) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Cellectis' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $21.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 58.34% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $21.3 million (up 58.34% YoY), while the FY2025 annual figure was $20.0 million, up 72.72% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $21.3 million, up from $20.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $21.3 million in Q1 2026, with the low at $499000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $11.6 million (2024), against an average of $12.3 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets slumped 97.74% in 2022, then jumped 3935.07% in 2023.
- Cellectis' Other Non-Current Assets stood at $8.8 million in 2022, then tumbled by 47.04% to $4.7 million in 2023, then soared by 149.01% to $11.6 million in 2024, then soared by 72.72% to $20.0 million in 2025, then gained by 6.3% to $21.3 million in 2026.
- Business Quant data shows CLLS's Other Non-Current Assets at $21.3 million in Q1 2026, $20.0 million in Q4 2025, and $18.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 21.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.29 Mn |
| Dec 31, 2025 | 20.03 Mn |
| Sep 30, 2025 | 18.18 Mn |
| Jun 30, 2025 | 16.13 Mn |
| Mar 31, 2025 | 13.44 Mn |
| Dec 31, 2024 | 11.59 Mn |
| Sep 30, 2024 | 11.12 Mn |
| Jun 30, 2024 | 4.66 Mn |
| Dec 31, 2023 | 4.66 Mn |
| Mar 31, 2023 | 20.14 Mn |
| Dec 31, 2022 | 8.79 Mn |
| Jun 30, 2022 | 9.09 Mn |
| Mar 31, 2022 | 499,000.00 |
| Dec 31, 2021 | 6.52 Mn |
| Sep 30, 2021 | 22.05 Mn |
| Jun 30, 2021 | 22.10 Mn |
| Mar 31, 2021 | 22.11 Mn |
| Dec 31, 2020 | 7.01 Mn |
| Sep 30, 2020 | 9.78 Mn |
| Jun 30, 2020 | 7.38 Mn |